IM Therapeutics to Present at LifeSci Partners Summer Symposium on August 4, 2020
WOBURN, MA – August 3, 2020 – ImmunoMolecular Therapeutics (“IM Therapeutics”), a leading innovator in the field of precision medicine for autoimmune disease, announced today that Dr. Nandan Padukone, CEO and Mr. Tom Shea, CFO/COO will be presenting updates of the Company at the LifeSci Partners Summer Symposium on August 4, 2020 at 4pm ET. LifeSci Partners Summer Symposium
About IM Therapeutics
IM Therapeutics is a clinical stage company developing personalized medicines for autoimmune diseases by building oral drug therapies against human leukocyte antigen (HLA) variants that confer high risk of disease. The Company platform screens millions of compounds for optimal docking within HLA proteins together with rational drug design and bioassays to develop targeted therapeutic candidates. In addition to its lead drug, IMT-002, directed at HLA-DQ8 activity for treatment of type 1 diabetes, the Company is building a broad pipeline of drugs against HLA targets such as DQ2, DR3 and DR4 in a range of autoimmune disorders including celiac disease. IMTherapeutics.com
Media Contact
IM Therapeutics
Susan Heins
Director, Media Relations
sheins@imtherapeutics.com
Tel: 864.346.8336